AstraZeneca Pharmaceuticals LP D0816L00003 Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 2 Prior Lines of Chemotherapy
Tashanna Myers, MD
D'Amour Center for Cancer Care
3350 Main Street
Springfield, MA 01199
This research study is designed to see if olaparib is effective in treating high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer and whether it causes any side effects. A capsule formulation of olaparib (tradename Lynparza™) is approved by both the European Commission (EC), US Food and Drug Administration (FDA) and other countries for the treatment of women with advanced BRCA-mutated ovarian cancer.
Diagnosis of platinum-sensitive epithelial ovarian, fallopian, or primary peritoneal cancer